An emerging challenge in neurodegenerative dementia is understanding how immune-associated genes and pathways contribute to disease. To achieve a refined view of neuroinflammatory signaling across neurodegeneration, we took an integrative functional genomics approach to consider neurodegeneration from the perspective of microglia and their interactions with other cells. Using large-scale gene expression and perturbation data, regulatory motif analysis, and gene knockout studies, we identify and characterize a microglial-centric network involving distinct gene co-expression modules associated with progressive stages of neurodegeneration. These modules, which are conserved from mouse to human, differentially incorporate specific immune sensors of cellular damage and pathways that are predicted to eventually tune the immune response toward chronic inflammation and immune suppression. Notably, common genetic risk for Alzheimer's disease (AD), Frontotemporal dementia (FTD) and Progressive Supranuclear Palsy (PSP) resides in specific modules that distinguish between the disorders, but also show convergence on pathways related to anti-viral defense mechanisms. These results suggest a model wherein combinatorial microglial-immune signaling integrate specific immune activators and disease genes that lead to the establishment of chronic states of simultaneous inflammation and immunosuppression involving type 1 interferon in these dementias.
Introduction
Leveraging genetic discoveries to identify therapeutic targets requires understanding how disease genes map onto cell-type specific molecular pathways. In this regard, a remarkable body of growing genetic evidence supports a link between Alzheimer's and associated dementias and neuroimmune functions involving glial cells 1, 2 Causal genetic variation in neurodegenerative dementias affects genes with neuralimmune functions affecting two major CNS resident neural immune cells, astrocytes and microglia, including, TREM2, GRN, HLA-DRA, CR1, C9ORF72, APOE, BIN1, CXCR4, CLU, and TBK1 [1] [2] [3] [4] [5] [6] . Multiple functional studies in animal models of neurodegeneration support the contribution of microglial and neural-immune genes to disease-associated phenotypes including age-associated cognitive decline, pathological protein deposition and dyshomeostasis, and neurodegeneration [7] [8] [9] . The discovery that immune-related genes contribute to AD and associated dementias has generated great enthusiasm for the possibility of immune-based therapies 10 . From this perspective, defining the detailed molecular relationship between disease-associated neuroimmune pathways and causal dementia genes has the potential to inform disease mechanism and inspire novel therapeutic approaches.
Microglia and CNS-resident macrophages are the principle immune cells of the brain with critical roles in detecting immunogens and coordinating the immune response 11 . During nervous system injury, microglia can be directly activated by myelin, lipids, or nucleotides released from injured cells to activate proinflammatory signaling, such as through the NLRP3 inflammasome complex 12, 13 . Experimental evidence in multiple models of AD pathology suggests that "disease-associated microglia" express dementia risk genes, including APOE and TREM2, and contribute to synaptic injury, neurotoxic astrocyte transitions, and neuronal dysfunction [14] [15] [16] [17] . Furthermore, single-cell genomic studies have begun to delineate heterogeneity among disease-associated microglial states and their trajectories, highlighting the need to better understand their specific roles in neurodegeneration 18, 19 . This includes defining how different microglial states relate to disease-associated immune activators and causal genes in human neurodegenerative diseases.
We recently used a systems biology approach to integrate gene expression data from human post mortem brain and multiple mouse models harboring human dementia causing mutations, to identify a robust neurodegeneration-associated inflammatory module (NAI) and a closely correlated neurodegenerationassociated synaptic module (NAS) 20 . The NAI module is strongly enriched for markers of both astrocytes and microglia, both of which are known to be significantly up-regulated in multiple neurodegenerative syndromes 9, 21, 22 . As a result of this global up-regulation within tissue, the cell-type specific expression patterns of glial genes in the NIA module were obscured. In silico approaches for deconvoluting cellspecific signatures are challenged by the complex dynamics among glial genes in disease 16, 18, 19, 23, 24 . So, we reasoned that the optimal resource for resolving glial pathways involved in neurodegeneration would be gene expression data from actual glial cell types isolated from disease and control samples.
Furthermore, given that neurodegeneration involves interactions between neurons and among glia 25 ; we reasoned that integrating data from sorted cells and intact tissue would reveal disease-relevant and cellspecific signaling networks.
Here we present an integrative analysis of microglial-specific transcriptomic changes that are latent components of neurodegeneration pathways at the tissue-level. Our findings parse disease genes into distinct microglial co-expression sub-networks (modules) related to progressive stages of neuropathology in mice that are conserved in humans. Using large-scale gene perturbation data, regulatory motif analysis, and knockout studies, we identify strong evidence for regulatory interplay that functionally connects different modules into a microglial-centered interactome. By incorporating genetic association data, we find that the genetic risk factors contributing to Alzheimer's disease (AD), Frontotemporal dementia (FTD) and Progressive Supranuclear Palsy (PSP) involved shared and distinct microglia-associated neuroimmune modules. However, as disease progresses, the associated shared transcriptional and PPI networks that are up-regulated involve chronic viral response pathways to double stranded RNA, likely driven by Type-1 interferon, supporting a model whereby early immune activation gives way to chronic immunosuppression in these disorders.
Results
We performed consensus weighted gene co-expression analysis (WGCNA 26 ; Methods) to combine gene expression data from sorted, purified microglia from a mutant tau mouse model (rTg4510; AMP-AD Knowledge Portal doi:10.7303/syn2580853) and whole brain tissue collected from multiple independent transgenic mouse models of neurodegenerative tauopathy (Methods, Figure 1A ) to identify conserved modules that exist in both purified microglia and tissue. We then used the microglia-specific gene expression data to identify up and down-regulated pathways ( Figure 1A , Schema). Using this approach, we identified 13 distinct co-expression modules varying in disease association, trajectory and time course (Fig 1B, 1C, 1D , 2A).
Consensus microglial modules combine cell-type specificity and tissue-level neuronal-glial relationships
We first focused on the 7 modules significantly enriched for genes expressed in microglia compared to other cell types 27 ( Fig. 1B, 1D ; Supplementary Fig. 1A ). As independent validation of cell-type trends, we assessed module enrichment for single cell microglial signatures, previously identified from high resolution single cell sequencing studies in mouse 28 and human 29 brain, and observed significantly greater marker enrichment among these 7 candidate microglia-gene enriched modules compared to the remaining modules (Fig. 1D, Supplementary Fig. 1A ). At the same time, these modules were distinct in that different modules overlapped with different sets of microglial signatures identified in previous single cell analyses 28, 29 suggesting that they represented distinct microglia pools (Fig. 1D, 2E, Supplementary Fig.   1A , 1G). For example, M_UP1 enriched for profiles of microglia proliferative states (clusters 2a, 2b, 2c) 28 and age-associated states identified previously in single cell transcriptome analyses (C8, aging_C1, aging_C2, aging_C3) 28 (Fig. 1D) .
We next tested whether our consensus modules recapitulate biological relationships present in tissuelevel neurodegeneration modules identified in prior studies (NAI and NAS) 20 . As expected, the seven microglia-enriched modules were highly positively correlated with the NAI inflammatory module and negatively correlated with the NAS synaptic module; both of which have been previously demonstrated to be conserved across humans with tauopathies and mice harboring mutations causing dominant forms of FTD in humans 20 (Fig. 1C) .
Next, we assessed each module's relationship to pathological neuronal Tau hyperphosphorylation, a measure of neuropathology associated with disease progression 30 . We found a strong positive correlation between pathological Tau phosphorylation levels and microglia-enriched consensus module gene connectivity ( Fig. 1E, Supplementary 1B) . In contrast, when we analyzed WGCNA modules generated using only sorted microglial cell gene expression data from the rTg4510 model, rather than consensus modules based on network edges shared between whole tissue and the sorted cell data, the correlation with pTau was substantially reduced (Fig. 1E) . This demonstrates the utility of using both cell specific and whole tissue data to advance our understanding of cell specific contributions to disease pathology.
Finally, we observed that the NAI and combined microglial consensus modules are conserved at the level of protein-protein interactions (PPI), which themselves coalesce into distinct molecular pathways (Fig. 1G,   Supplementary Fig. 1C ). Thus, these seven co-expression modules represent a substantial refinement of a previously identified neural immune module observed in both model systems and post mortem human brain [18] [19] [20] 31, 32 . We label the seven new modules "microglia-associated neurodegeneration-associated modules" (MNMs, 1-7), and further characterized them as a means to explore associated microglial functional pathways and regulators related to neurodegeneration.
MNMs are conserved in human disease brain and mouse models
To assess the robustness of the microglia-enriched modules and further validate their relevance to human disease, we tested their preservation using multiple independent mouse and human disease datasets (see Fig. 1D ) and in microglial-specific datasets from mouse models expressing PSEN 36 and APP 37 mutations, except M_UP3, which is only weakly preserved in one of two datasets ( Supplementary Fig. 1E ). However, we do note that the differential expression patterns of three modules (M_UP2, M_UP3, M_DOWN3) differ between microglia isolated from P301L MAPT (rTg4510) and PSEN/APP mutant mouse models (Supplementary Fig. 1F ). Together, the preservation of these modules across multiple independent disease datasets including human disease brain from Alzheimer's and associated dementias and mouse models of Alzheimer's or FTD, as well as PPI, indicates that they represent robust biological processes. However, some modules display variability in their differential expression in different disease models, suggesting they may be conditional on disease-stage or diseasespecific pathology.
Microglial molecular transitions along progressive epochs of neuronal pathology
In contrast to the composite whole tissue NAI module expression vector which shows a singular increasing trajectory over time (shown in 20 ), we were able to deconvolute the MNM modules into highly distinct temporal trajectories with respect to progressive disease stages modeled in the rTg4510 mouse between 2 and 8 months of age 35, [38] [39] [40] . We identified three temporal patterns of module-disease association: (1) changing at the earliest disease stage, prior to neuronal loss, and persistent through later stages (M_UP1, M_DOWN1, M_DOWN2), (2) changing during early periods of neuronal loss, and more transient (M_UP2, M_DOWN3), and (3) most significant changes during late stages of continued neuronal loss and cumulative pathology (M_UP3) (Fig. 2A) . Therefore, combined tissue-microglial cell consensus WGCNA resulted in microglial neurodegeneration-associated modules with distinct temporal transitions across disease progression, which were present in latent forms, but not detected in the analysis of whole tissue alone.
To validate our MNM-disease stage trends using complementary published datasets, we compared them to time-course, single-cell microglial differential gene expression data collected from two different mouse models with Alzheimer's related pathology (5xFAD 18 , CK-p25 19 ), including one model with frank neurodegeneration (CK-p25 19 ). As expected, the early up-regulated MNM, M_UP1, is enriched for genes that are increased in early microglial disease states relative to homeostatic microglia (Fig. 2E,   Supplementary Fig. 1G ), and the later up-regulated MNMs are enriched for genes up-regulated in later relative to early microglial disease states (Fig. 2E, Supplementary Fig. 1G ). The four down-regulated MNM are all enriched for microglial genes down-regulated in early microglia disease states (Fig. 2E,   Supplementary Fig. 1G ).
We next leveraged published data on the type 2 interferon response to ask whether MNMs reproduce the late interferon-gamma signature reported to distinguish microglia during periods of neuronal cell death 19 . We were able to show that the last up-regulated MNM in disease, M_UP3, is also the only module induced by interferon-gamma treatment of cultured microglia 41 ( Fig. 2F) 
Pathway analysis to expand biological insights into microglial transitions across disease
Annotation of modules for enriched biological regulators and pathways aligned specific disease genes, signaling and functional pathways, immune receptors, transcription factors and microglia-enriched gene co-expression modules with progressive stages of neuronal dysfunction and degeneration that are summarized in Figure 2 ( Fig. 2A, 2B , 2C, 2D, 2F, 2G, Supplementary Fig. 2A, 2B ). These annotations indicate that each of these modules represents different aspects of the microglia function that vary across disease stage, with different microglial modules poised to sense and respond to specific damageassociated immune activators 12, 42 that change over time ( Fig. 2A, 2C, 2G ).
For example, the earliest up-regulated module, M_UP_1, incudes sensors of peptide and lipopeptide immune activators (TLR1, TLR2), whereas the subsequently up-regulated module, M_UP2, includes sensors of lipid immune activators (TREM2, SCARB2) together with receptors for viral nucleotides (TLR7, TLR9, Ifih1) that can also be activated by damaged or dysregulated endogenous DNA 12, [42] [43] [44] [45] [46] . Therefore, our microglial time-course analysis shows a prominence of DNA and RNA detecting immune receptors within the second phase of up-regulated MNMs, suggesting that nucleic acids activate inflammatory pathways as neuronal injury and disease progress (Fig. 2G) . Additionally, we find that these sensors are co-expressed with genes associated with specific signaling pathways as disease progresses (Fig. 2C, 2D , Supplementary Fig. 2A, 2B ). For example, M_UP1 is enriched for genes related to the IL1 signaling pathway and complement cascades, whereas M_UP2 is enriched for genes of the IL6 signaling pathway and phagocytosis (Fig. 2C, 2D, Supplementary Fig. 2B ).
MNMs also provide refinement of previously reported microglial changes during disease 18, 19 . For example, down-regulation of homeostatic microglial markers previously reported in disease 18, 47 , is split between two modules, M_DOWN1 and M_DOWN2, that represent distinct biological pathways (e.g. M_DOWN1
for prostaglandin synthesis and phagocytosis; M_DOWN2 for natural killer cell activation and positive cell cycle regulation; Fig. 2C, 2G, Supplementary Fig. 2A, 2B ) and respond differently to microglial stimulation by Abeta42 and IL-4 in cell culture (Supplementary Fig. 2C ). Lastly, we note that known common and Fig 3A) . For example, perturbation of genes in the earliest upregulated module, M_UP1, significantly upregulates genes within the subsequently up-regulated modules (M_UP2 and M_UP3) and downregulates genes within the down-regulated modules (M_DOWN1, Fig 3A; Methods). These observations that genes within the early up-regulated MNMs can drive later MNMs suggests that MNMs capture transitions from early microglial states that drive subsequent states as disease progresses.
M_DOWN2, M_DOWN3, M_DOWN4) (Supplementary
To further delineate microglial transitions captured by MNMs, we assessed their gene promoters for shared experimentally validated transcription factor binding sites (TFBS). Nearly all MNMs showed high TFBS overlap, consistent with shared transcriptional drivers. However, two modules, M_UP1 and M_UP2
had genes with very distinct TFBS enrichments from each other (Supplementary Fig. 3B ). This was despite substantial direct PPI connections between the modules (Supplementary Fig. 3C ) and evidence of positive driver effects of M_UP1 genes on M_UP2 expression (Supplementary Fig. 3A) . Therefore, while early
MNMs are poised to be highly integrated at the level of regulatory drivers with later or concurrent, MNMs, M_UP1 and M_UP2 appeared to be driven by distinct candidate regulators.
Identification of the inflammasome and anti-inflammasome related modules
To assess potential regulatory cross-talk among M_UP1 and M_UP2 genes in more detail, we re-clustered their genes to highlight any co-expression relationships that may exist between them ( Fig. 3A ; Module A and Module B). This resulted in two modules that are both up-regulated early in disease with nearly identical trajectories (Fig. 3B, 3D ), but with strongly anti-correlated gene-module connectivity (anticorrelating kME, Fig. 3C ), suggestive of opposing or competing pathways 26 . This is not an artifact of our transcriptional analysis, as independent CMAP gene perturbation experiments validate that gene overexpression has opposing effects on the genes clustered within these two modules ( Fig. 3F; Methods) .
Other independent data confirm these relationships, in single cell RNA sequencing studies of mouse 28 and human brain 29 (Fig. 3E, Supplementary Fig. 4C) , and at the level of PPI (Supplementary Fig. 4A ). , verify their robustness across mouse models of dementia and their relevance to human disease ( Supplementary Fig. 4B, 4D ). These findings support the identification of two highly conserved microglialenriched modules that are up-regulated in disease, but that include polarized signaling pathways, which we hypothesized were poised for regulatory cross-talk.
Module annotation and pathway analysis (Methods) identified the NLRP3 inflammasome and type 1-interferon response pathways as defining core components of these two modules (Fig. 3G, 3H ), which we accordingly named the "inflammasome" and "anti-inflammasome" modules. The NLRP3 inflammasome is assembled downstream of cellular stressors and activated by the detection of various stimuli 13 , including pathological Abeta 49, 50 , to promote pro-inflammatory states. Similarly, pathological Abeta rapidly and specifically stimulates the expression of the inflammasome module eigengene in microglia, both in vivo and in vitro (Fig. 3I, Supplementary Fig. 4F ). In contrast, the prominent pathway within the antiinflammasome module is the type-1 interferon response. Microglial isolated from mice overexpressing beta-interferon show both up-regulation of the anti-inflammasome module and down-regulation of the inflammasome module, in a manner dependent on the type 1 interferon receptor, IFNAR1 (Fig. 3J) .
Consistent with this finding, type 1 interferon is a known suppressor of the NLPR3 inflammasome 51 , and NLPR3 inflammasome activation has recently been shown to inhibit type 1-interferon signaling 52 .
Furthermore, at the center of the anti-inflammasome module PPI map is MDA5 (Ifih1), a receptor of dsRNA that can activate type 1 interferon response downstream of viral detection or chromatin destabilization 44, 45, 53 (Fig. 4B) . These data provide multiple lines of evidence supporting that these two early up-regulated microglial modules represent opposing states, likely orchestrated, at least in part, by type 1 interferon signaling as a key polarizing driver.
Type 1 interferon is not only a classic activator of acute anti-viral immunity, but more recently it has been demonstrated to be a critical driver of immunosuppression in the context of chronic viral infections 54, 55 .
Several features of the anti-inflammasome module suggest it too may represent aspects of interferonmediated immunosuppression, including its anti-correlation with the inflammasome module, and its inclusion of genes that function as immune checkpoints (Cd274 (PDL1), Il10rb, Lag3) 54,56-58 and inhibitors of immune activity (Usp18 [59] [60] [61] [62] , Nfkbiz, Nfkbia, Nfkbie, Tgfbr2 63, 64 ). Among these genes is Usp18, an established negative feedback suppressor of type 1 interferon anti-viral immune activity [59] [60] [61] [62] 65, 66 that is also highly connected with the anti-inflammasome module in microglia treated with interferon-beta ( Supplementary Fig. 4G ). Consistent with Usp18 being a critical driver of the anti-inflammasome module, we found that gene co-expression relationships in the anti-inflammasome module are completely disrupted by Usp18 knockout, without any effect on the inflammasome module (Fig 4C) . Furthermore, the inflammasome module is highly up-regulated in the Usp18 knockout mouse in an IFNAR1 dependent fashion, suggestive of "hyperimmune" activation of the inflammasome module in the absence of Usp18 and the anti-inflammasome module (Fig. 4D) . These data strongly support a mechanistic model, wherein interferon beta drives the anti-inflammasome and inhibits the inflammasome module through activation of immune suppressors, including Usp18, implicating interferon beta as a potential suppressor of immune activity in the chronic phase of neurodegenerative tauopathies (Fig. 4E) , similar to what has been reported in chronic viral infections 62, 65, 66 .
Viral response mechanisms link genetic risk factors across different Tau-associated dementias
Since gene expression changes on their own may represent causal, reactive or compensatory changes, we integrated genome-wide common genetic risk using MAGMA 67 to identify whether any of the identified Fig. 5C, 5D ). We next tested all MNMs, including the early submodules, for module-wide enrichment of disease risk genes associated with FTD, AD and PSP compared to controls, based on published GWAS studies [68] [69] [70] (see Methods, Figure 5A ). We found that the common genetic risk associated with AD, FTD and PSP is not randomly distributed, but shows distinct patterns of enrichment:
AD risk with M_UP3, FTD risk with early_UP1, FTD risk with early_DOWN1, PSP risk with early_DOWN1
( Fig. 5A) . Each of these modules links distinct glial immune-related genes and associated pathways to disease causality, including increased exogenous antigen presentation and viral defense with AD, increased microglial immune activation and phagocytosis with FTD, and suppressed anti-viral response with both FTD and PSP (Fig. 5B, 5C ).
To independently validate these disease-module relationships, we performed confirmatory testing using a cross-disorder exome array dataset that included AD, FTD, PSP and control cases 71 . The exome array data confirmed significant associations between AD and M_UP3 (beta = 0.19 p<0.001; Supplementary Fig.   5F ), FTD and early_UP1 (beta = 0.25, p<0.001) and FTD and early_DOWN2 (beta = 0.15 p<0.001) (Supplementary Fig. 5F ), but not PSP, perhaps because the exome array data set is too small and therefore underpowered for PSP 71 (Methods). Providing additional validation is the presence of transcription factors within these modules that are capable of inducing the disease-associated microglia gene expression patterns, including Spi1(PU.1) 72 within the AD associated module (M_UP3) and Zeb2 within the FTD and PSP associated module (early_DOWN1) (Fig. 5B, Supplementary Figure 5G ).
We note that viral response is a commonality among the modules enriched for common genetic variants contributing to susceptibility for these three dementias that involve tau pathology, albeit to different extents (M_UP3, and early_DOWN1) (Fig. 5B, 5C ). This suggested a potential causal relationship between tauopathy and viral response. In the case of AD, the causal association is with late up-regulated viral response pathways, whereas for FTD and PSP the causal association is with early down-regulated antiviral response pathways (Fig. 5B, 5C, Supplementary Figure 5E ). To test whether viral response pathways were also engaged by pathological Tau, we identified the biological pathways most correlated with Tau hyperphosphorylation in the TPR50 mouse brain (Methods), and indeed observed that genes involved with virus detection and anti-viral response were enriched (Supplementary Figure 5H ,I,J), consistent with the activation of viral response pathways in concert with tau pathology in disease tissue.
Discussion
Through an integrative systems biology approach, we have identified microglia immune networks related to specific stages of neurodegeneration modeled in mice harboring mutant Tau protein.
Combining whole tissue and cell type specific data from multiple divergent mouse transgenic lines and strains, we identified seven conserved microglia modules that were also represented in post mortem tissue from patients and controls. By integrating data from brain tissue with sorted cell data, we achieved a unique perspective on neuroinflammatory signaling in neurodegeneration that we show neither can achieve on its own. Our results delineate a detailed time-course of microglial transitions across stages of progressive disease pathology that highlight specific immune receptors, biological pathways and regulatory factors at each stage. Furthermore, although each of the modules captures distinct pathways, our analysis of regulatory overlap suggest they are not entirely isolated, but rather are highly linked pathways, whose central components and core hubs transition as disease progresses through different stages. Within this robust framework, MNNs differentially implicate human disease genes with specific neuroimmune pathways that both recapitulate prior known biological relationships and identify new relationships between specific neuroimmune pathways and different disorders for further study.
Our refined analyses of microglia-associated changes across tauopathy suggest that early immune activation gives way to chronic immunosuppression, potentially driven by activation of interferon beta downstream of cytosolic dsRNA detection. In support of this is the observation that interferon beta acting through IFNAR1 is a known driver of chronic inflammatory states in cancer and chronic viral infection 54 .
Furthermore, dsRNA detection can trigger interferon beta downstream of chromatin destabilization 53 .
Here we find that interferon beta activates genes in the anti-inflammasome pathway capable of blocking hyperimmune activation, including Usp18
60
, and suppresses genes of the inflammasome module that participate in innate immunity. Furthermore, we find the cytosolic dsRNA receptor Ifih1 (MDA5) and associated RIG1 pathway at the core of the anti-inflammasome module PPI, and both dsRNA detection and interferon pathways to be highly correlated with pathological Tau burden ( Supplementary Fig. 5H , 5I, 5J). These observations suggest that factors related to the accumulation of pathological Tau might trigger the interferon pathway through dsRNA detection. This is particularly salient based upon the recent observation that pathological Tau drives chromatin destabilization 73, 74 , a known source of endogenous dsRNA that can activate Ifih1 (MDA5) and trigger an interferon response 44, 53 . Combined, our results present a parsimonious model wherein dsRNA, released following chromatin destabilization in injured neurons in response to Tau pathology, may active chronic immune activation pathways to suppress specific immune signaling (the inflammasome module) and activate anti-inflammasome pathways to alter cellular functions including protein ubiquitination, autophagy, exosome formation, and translation 75 ( Fig.   4E ). These observations predict that inhibition of the anti-inflammasome module, either through blockade of dsRNA, IFNAR1, or immune checkpoints within the module (PD-L1) would reduce progressive immune dysregulation triggered by pathological Tau and, at least in part, restore homeostatic microglia damage response mechanisms. These observations suggest an important causal connection between pathological Tau, viral control and the interferon response that has not previously described. Interestingly, interferon has also been implicated as a driver of microglial dysfunction in aging, suggesting interferon-driven immunosuppression in aging may also contribute to age related susceptibility to neurodegeneration 7 .
Future functional and mechanistic studies will be needed to experimentally test and extend these observations, but they have potential therapeutic implications.
Genetic risk factors for AD, FTD and PSP further implicate roles for viral defense mechanisms in causal disease biology. Interestingly, the specific genes and pathways implicated differ between AD and FTD/PSP. AD genetic risk factors causally implicate antigen presentation pathways that increase in late stages in tauopathy models, whereas FTD and PSP risk factors converge upon anti-viral genes that are down-regulated in microglia very early in the mouse tauopathy models. Our findings suggest for the first time that early loss of specific anti-viral and microglial maintenance factors may be causal contributors to disease progression early in primary tauopathies.
Our findings predict that microglia may contribute to disease in a stage-specific manner by linking progressively changing disease-associated stimuli into an integrated, multi-cellular signaling network that sets the chronic course of dementia. More specifically, our observations suggest that early in tauopathy there is loss of microglial homeostasis including specific viral defense functions that promote disease progression. Further, as disease progresses and pathological Tau accumulates, it drives activation of dsRNA detection pathways, possibly through chromatin destabilization 53 , to further suppress healthy immune functions and contribute to cellular dysfunction and disease propagation. From this perspective, different stages of dementia are associated with different levels of immune activation, and as disease progresses into its clinical phase, these analyses suggest that it is likely a state of chronic immune suppression that may promote disease progression and contribute to chronic cellular dysfunction, rather than immune activation.
Methods

Data Set Acquisition and Filtering
Both RNAseq datasets used as input for consensus WGCNA were previously generated. The TPR50 dataset 20 includes gene expression data from frontal cortex dissected from male mice expressing P301S
MAPT or WT controls (TPR50 transgenic model 76 Additional publicly available datasets were used throughout the study for validation or comparison.
Mouse datasets consist of microarray or RNAseq transcriptomics data from a variety of transgenic mice Microarray or RNAseq datasets downloaded from the Gene Expression Omnibus (GEO) were read into R and processed as follows. Microarray data were log2-transformed and normalized by quantile normalization. Gene counts were filtered to remove low read counts (>80% of the sample with > 10 reads wth HTSeq quantification), corrected for guanine-cytosine content, gene length and library size, and log2-transformed using the CQN package in R 81 . The resulting data was used as an input to test module preservation, average gene expression and/or eigengene expression.
mRNA Weighted Co-expression Network Analysis
In order to identify gene co-expression networks present both in purified microglia and frontal cortical brain tissue, and across multiple transgenic mouse strains and genetic backgrounds, we utilized consensus WGCNA as previously described 20 using the WGCNA R package
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, applied to the TPR50 dataset of forebrain
RNAseq from mice aged 6 months, and the Tg4510 dataset of purified microglia (2,4,6 and 8 months), described above. The input data were generated from (1) Biweighted mid-correlations were calculated for all pairs of genes, and then assigned similarity matrices were created using the Consensus WGCNA method as previously described 82 . In the signed network, the similarity between genes reflects the sign of the correlation of their expression profiles. The signed similarity matrix was then raised to power β to emphasize strong correlations and reduce the emphasis of weak correlations on an exponential scale. A thresholding power of 14 was chosen (as it was the smallest threshold that resulted in a scale-free R2 fit of 0.8) and the consensus network was created using the function blockwiseConsensusModules() to calculate the component-wise minimum values for topologic overlap (TOM), with parameters set as networkType = "signed", deepSplit = 2, detectcutHeight = 0.995, consensusQuantile = 0.0, minModulesize = 100, mergeCutHeight = 0.2. Using 1 − TOM (dissTOM) as the distance measure, genes were hierarchically clustered. The resulting modules or groups of coexpressed genes were used to calculate module eigengenes (MEs; or the 1st principal component of the module). Modules were annotated using the GOElite package 83 . We performed module preservation analysis using consensus module definitions 84 . MEs were correlated with transgenic condition to find disease-associated modules. Module hubs were defined by calculating module membership (kME) values which are the Pearson correlations between each gene and each ME. Gene expression was correlated with pT231 Tau levels measured by ELISA to calculate the "gene significance" relationship with pT231 Tau, as defined by the WGCNA method 26 , using gene expression data from the TPR50 model (6 months, n=36), and this was further correlated (Pearson's) with kME to assess the relationship between pT231 Tau and gene-module connectivity. All network plots were constructed using the Cytoscape software 85 . Module definitions from the network analysis were used to create synthetic eigengenes from which to calculate the expression trajectory of various modules in different gene expression datasets.
Clustering of gene subsets
To apply gene co-expression methods to understand co-expression relationships among subsets of module genes in either the original consensus dataset, or in the TPR50 dataset of pre-symptomatic mice at 3 month of age, we again used the WGCNA package 26 . Biweighted mid-correlations were calculated for a subset of genes from selected consensus modules to create an adjacency matrix that was further transformed into a topological overlap matrix (with TOMType = "unsigned"). Using 1 − TOM (dissTOM) as the distance measure, genes were hierarchically clustered using the following parameters (deepSplit = 2, detectcutHeight = 0.999, minModulesize = 40, dthresh=0.1, softPower =7). The resulting modules, or groups of co-expressed genes, were used to calculate module eigengenes (MEs; or the 1st principal component of the module). The significance of intramodular connectivity was assessed for each module using a permutation test (10,000 permutations), and all modules were confirmed to have permuted pvalue <0.001. "Early submodules", described in Figure 5 and Supplementary Figure 5 , were derived by reclustering M_UP1 and M_UP2 genes to generate "earlyUP" modules, or M_DOWN1, M_DOWN2 and M_DOWN3 genes to generate "earlyDOWN" modules, in the 3 month of age frontal cortex TPR50 dataset previously described 20 . "Inflammasome and anti-inflammasome modules", described in Figure 3 -4, were derived from re-clustering M_UP1 and M_UP2 genes in the consensus WGCNA input datasets (purified microglia from the Tg4510 model and frontal cortex TPR50 dataset (6 months of age)).
Module Preservation Analysis
We used module preservation analysis to validate co-expression in independent mouse and human datasets. Module definitions from consensus network analysis were used as reference and the analysis was used to calculate the Zsummary statistic for each module. This measure combines module density and intramodular connectivity metrics to give a composite statistic where Z > 2 suggests moderate preservation and Z > 10 suggests high preservation 84 .
Module Gene Set Enrichment Analysis
Gene set enrichment analysis was performed using a two-sided Fisher exact test with 95% confidence intervals calculated according to the R function fisher.test(). We used p values from this two-sided approach for the one-sided test (which is equivalent to the hypergeometric p-value) as we do not a priori assume enrichment 86 . Zeb2 knockout compared to control microglia, we used the published set of differentially expressed genes 77 . The background applied for over-representation analyses was set as the genes input into the consensus analysis (overlap of genes expressed in Tg4510 microglia and TPR50 frontal cortex RNAseq datasets).
Gene set annotation
Genes in network modules were characterized using GO-Elite (version 1.2.5), using as background the set of input genes used to generated the modules being annotated 83 . GO-Elite uses a Z-score approximation of the hypergeometric distribution to assess term enrichment, and removes redundant GO or KEGG terms to give a concise output. We used 10,000 permutations and required at least 3 genes to be enriched in a given pathway at a Z score of at least 2. We report only biological process and molecular function category output.
Protein-Protein Interaction Analysis
To assess and visualize protein-protein interactions among module genes, we used STRING (version 10.5;
https://string-db.org) 88 with the following setting (organism: Mus musculus; meaning of network edges:
confidence; active interaction sources: experiments and databases; minimal required interaction score: medium confidence (0.400), max number of interactors to show: none). Data was exported and visualized using the Cytoscape software 85 .
Transcription Factor Binding Site Enrichment Analysis
Transcription Factor Binding Site (TFBS) enrichment analysis using an in-house package that incorporates TFBS as previously described 89 . Briefly, we utilized TFBS position weight matrices (PWMs) from JASPAR and TRANSFAC databases 90, 91 to examine the enrichment for TFBS within each module using the Clover algorithm 92 . To compute the enrichment analysis, we utilized three different background datasets (1000 bp sequences upstream of all mouse genes, mouse CpG islands, and mouse chromosome 20 sequence).
We plotted significant TFBS-module pairs (TFBS p-value < 0.05, compared to all mouse CpG islands), for
TFs shared between multiple modules, as a network plot in Cytoscape, with edges connecting TFs and modules and edge weights proportional to the negative log10(p-value).
Connectivity Map (CMAP) Analysis
For a given module, the top 150 module genes (ranked by kME) were used as input for the QUERY app in the Broad's CMAP database, version CLUE (https://clue.io) 93 . This signature was used to query 7,494 gene overexpression or knockdown experiments carried out across 9 cell lines for similar (positive connectivity score) or opposite (negative connectivity score) effects on gene expression signatures, incorporating
Kolmogorov-Smirnov statistics (a nonparametric, rank-based pattern-matching strategy) as described 48, 93 .
Mean "connectivity scores" across all cell lines was ranked by increasing order of connectivity to the input module gene expression signature to generate a rank ordered list of signed perturbagen-module connectivity scores. To identify module genes whose perturbation could reproduce the differential expression patterns of module seen in disease, we identified genes from up-regulated disease modules whose overexpression in CLUE had positivity connectivity scores with up-regulated modules or negative connectivity scores with down-regulated modules, and genes from down-regulated disease modules whose down-regulation in CLUE (via shRNA) had positive connectivity scores with signatures from upregulated modules and negative connectivity scores with signatures from down-regulated modules, using a connectivity score cut off of |70|. Gene perturbation-module connectivity was plotted with edge length = -log10(|connectivity score|), using Cystoscope.
MAGMA
Summary statistics for genome-wide association studies for AD 70 , PSP 69 and FTD 68 were used as an input for MAGMA (v1.06) 67 for gene annotation to map SNPs onto genes (with annotate window = 20,20) and the competitive gene set analysis was performed to test module associations with GWAS variants (permutations = 100,000). All genes assigned to a given module were used as the input for each module.
Consensus modules and re-clustered modules were run as separate groups in MAGMA given that they contain overlapping genes. Additional FDR correction was applied across all the competitive p-value outputs from MAGMA for all modules used in the study. 
Exome-based validation of MAGMA disease-module associations
ELISA
Total tau and pT231 tau content were measured by commercial tau ELISA kits according to the manufacturer's instructions (total tau -KHB0041; pT231 tau -KHB8051, Invitrogen). Briefly, standards, RIPA-soluble or sarkosyl insoluble samples were applied to the ELISA plate. After washing, a biotinconjugated detection antibody was applied. The positive reaction was enhanced with streptavidin-HRP and colored by TMB. The absorbance at 450 nm was then measured and the concentration of tau protein was calculated from the standard curve.
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